SIOX News and Press, Sio Gene Therapies Inc. From 10/14/22

Cheap Penny Stocks to Buy For Under $1 If you’re watching the action in the stock market today, you’re seeing plenty of chop. The U.S. dollar’s strength has pushed broader markets lower, but a mix of positive and negative economic against this week’s PPI data...

Sio Gene Therapies press release ( NASDAQ: SIOX ): Q1 GAAP EPS of -$0.11 beats by $0.08 . As of June 30, 2022, we had $54.8 million of cash and cash equivalents. For further details see: Sio Gene Therapies GAAP EPS of -$0.11 beats by $0.08

— Strong cash position with $54.8 million of cash and cash equivalents as of June 30, 2022, expected to provide cash runway beyond August 2023 NEW YORK, N.Y. and DURHAM, N.C., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX) today provided financial re...

Sio Gene Therapies press release (NASDAQ:SIOX): Q4 GAAP EPS of -$0.18 misses by $0.01. As of March 31, 2022, the company had $63.7 million of cash and cash equivalents. Shares +2% PM. For further details see: Sio Gene Therapies GAAP EPS of -$0.18 misses by $0.01

NEW YORK and DURHAM, N.C., June 14, 2022 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX) today provided financial results for its fiscal year ended March 31, 2022. Fiscal Fourth Quarter Financial Summary For the fourth fiscal quarter ended March 31, 2022, research a...

A group of biotechs focused on gene therapy candidates surged on Tuesday after the FDA posted a favorable review on a β-thalassemia candidate developed by commercial-stage company Bluebird bio (NASDAQ:BLUE) ahead of an AdCom meeting later this week. The data for the marketing applicati...

Shares of Sio Gene Therapies (NASDAQ:SIOX) fell 24.8% to $0.45 in aftermarket trading on Wednesday, after the company terminated its licensing agreement with the University of Massachusetts to make and sell gene therapy product candidates for the treatment of GM1 and GM2 gangliosidosis. ...

-Company Announces Termination of Licensing Agreement for GM1 and GM2 Gene Therapies with the University of Massachusetts -Company has engaged SVB Securities to advise it on a range of strategic alternatives to maximize stockholder value -Company had cash and cash equivalents ...

Not long ago, PASG was awarded a $1.2B enterprise value by the market. Though the company made progress, the vagaries of the market are such that it now trades at a negative enterprise value. I survey the company and its programs to find reasons to monitor its progress with the po...

Sio Gene Therapies press release (NASDAQ:SIOX): Q3 GAAP EPS of -$0.35 misses by $0.12. Cash and cash equivalents of $81.9M as of December 31, 2021  Shares -2.50% PM. For further details see: Sio Gene Therapies GAAP EPS of -$0.35 misses by $0.12